Last reviewed · How we verify
PHP-201 ophthalmic solution
PHP-201 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms.
PHP-201 is an ophthalmic solution designed to treat ocular surface disease, likely through anti-inflammatory or lubricating mechanisms. Used for Ocular surface disease (presumed, based on formulation type).
At a glance
| Generic name | PHP-201 ophthalmic solution |
|---|---|
| Also known as | Sovesudil |
| Sponsor | pH Pharma |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for PHP-201 are limited in public literature, ophthalmic solutions in phase 3 development typically work by reducing ocular surface inflammation, enhancing tear film stability, or promoting corneal epithelial healing. The exact molecular target and mechanism for PHP-201 require access to clinical trial protocols or company disclosures.
Approved indications
- Ocular surface disease (presumed, based on formulation type)
Common side effects
Key clinical trials
- A Study of Efficacy and Safety of PHP-201 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma (PHASE2)
- PK/PD, Safety and Tolerability of PHP-201 Topical Eye Drop in Korean and Japanese Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PHP-201 ophthalmic solution CI brief — competitive landscape report
- PHP-201 ophthalmic solution updates RSS · CI watch RSS
- pH Pharma portfolio CI